Pcn288 - Has the New Nice Appraisal Process for Oncology Drugs Delivered Faster Patient Access to Innovative Treatments?

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.370
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Pcn302 - Is the New Nice Appraisal Process for Oncology Indications Too Positive in Its Assessment of Cancer Drugs in England?

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

A Loss of Chance Index: A New Tool for Optimizing Patient Access to Innovative Drugs

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Pcn299 - A Review of Appraisal Timelines in Oncology: Does Reimbursement Through the Cancer Drugs Fund (Cdf) Delay Patient Access?

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Evidence That Werewolves Affect the Nice Appraisal Process

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Php279 - Assessment of the Nice Fast-Track Appraisal (Fta) Process

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

HAS to Be NICE?

European Journal of Health Economics
Health PolicyEconomicsEconometricsFinance
2013English

Proposals on Faster NHS Access to New Medicines

Prescriber
Pharmacology
2017English

Pcn239 - Nice and the Cancer Drugs Fund: Appraising Treatments for Rarer Cancers in England

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pcn230 - Are Nice and the SMC Diverging in Their Assessment of Oncology Drugs?

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy